Chronic hepatitis C patients with sustained virological response (SVR) after treatment may still be at risk of hepatocellular carcinoma (HCC), a new study reports. Risk factors include a lower platelet count, cirrhosis and elevated aspartate aminotransferase (AST) levels.
Both structured lifestyle intervention and liraglutide treatment induced significant weight loss in obese, nondiabetic Asian patients with nonalcoholic fatty liver disease (NAFLD), according to a pilot randomized trial.
Larotrectinib delivers durable response across diverse cancer types, including paediatric and adult cancers, according to an interim analysis of three ongoing trials presented at the ASCO 2017 Annual Meeting.
Selective internal radiation therapy (SIRT) did not fare better than sorafenib in terms of overall survival (OS) in patients with locally advanced hepatocellular carcinoma (HCC), though it appeared to be associated with fewer total adverse events, according to findings of the phase III, multicentre (11 Asia-Pacific countries), open-label SIRveNIB* study.
Treatment with capecitabine after surgery for biliary tract cancer improves overall survival (OS) by 15 months compared with observation after surgery, according to the BILCAP* study presented at the ASCO 2017 Annual Meeting in Chicago, Illinois, US.
The minimally invasive laparoscopic liver resection (LLR) appears to be a safe and feasible alternative to open liver resection (OLR) for patients with liver metastasis from colorectal cancer (CRC), according to a study.
A genetic variant in the tolloid like 1 (TLL1) gene is strongly associated with the development of hepatocellular carcinoma (HCC) after the eradication of hepatitis C virus (HCV) infection by interferon-based therapy, according to a genome-wide association (GWAS) study.
Adolescent males with a high body mass index (BMI) appear to be at a greater risk of severe liver disease including hepatocellular carcinoma (HCC), and this risk is more pronounced in men who develop type 2 diabetes mellitus (T2DM), according to a population-based cohort study.
The first NGO joint forum at the Asian Pacific Association for Study of the Liver (APASL) conference recently aims to build collaboration in support of national hepatitis policymaking and service delivery.
Treatment with low-dose on-demand hepatitis B immunoglobulin added to entecavir led to decreased hepatitis B virus (HBV) recurrence rate without development of resistance following liver transplantation, according to an assessment of a pilot study.
Sanofi’s approach in providing medical education has evolved over the years, by not only limiting the content to disease management and patient outcomes, but also taking into consideration of the various challenges faced by doctors across the different sectors.
Excerpted from a speech by Datuk Seri Dr. S. Subramaniam, Minister of Health, at the launch of the new palliative care symbol and palliative care photography exhibition by Hospis Malaysia, Kuala Lumpur, 25 April